Quantcast

Junshi Biosciences and Merck Announce Collaboration to Explore Promising New COMBINATION Treatment for Head and Neck Cancer Patients in China

SHANGHAI, China, June 01, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEK: 1877), a China-based biopharmaceutical company specializing in discovery, development and commercialization of novel therapies, and Merck, a world leading science and technology company, today announced their collaboration on a clinical trial program designed to investigate the efficacy and safety of anti-PD-1 mAb toripalimab (TUOYI®) in combination with Cetuximab (Erbitux®) as a treatment for recurrent and/or metastatic squamous cell carcinomas of the head and neck (R/M SCCHN) in China.

Head and neck cancer is one of the most common cancer types in China, ranking 7th in terms of incidence and mortality1. Each year, there are more than 135,000 new cases and about 70,000 deaths1. And the vast majority (more than 90%) are squamous cell carcinomas2. Head and neck cancers are highly heterogeneous and vary across subsites, leading to a potentially devastating impact on patients’ physical and psychological well-being, as well as overall quality of life. Anti-EGFR monoclonal antibody and PD-1 inhibitors have been proved effective in the treatment of R/M SCCHN. However, there are still unmet needs for better treatment options to further improve patients’ response, prolong survival, and improve their quality of life.

Cetuximab (Erbitux®) is an IgG1 monoclonal antibody that specifically targets the EGFR. The inhibition of EGFR blocks the processes involved in tumor cell growth and progression. Cetuximab is also a potent inducer of antibody-dependent cell mediated cytotoxicity (ADCC), inducing antitumor immune effect. In February 2020, Cetuximab was granted an approval by China’s National Medical Products Administration (NMPA) for the first-line treatment of R/M SCCHN using a combination chemotherapy regimen (platinum plus 5-FU).

Developed by Junshi Biosciences, toripalimab (TUOYI®) is the first domestically marketed PD-1 monoclonal antibody in China. Anti-PD-1 mAb is an immunotherapy that can activate and direct the body’s own immune system to attack tumor cells by inhibiting the PD-1 pathway. Over 30 toripalimab mono and combo clinical trials have been conducted globally for more than 10 tumor types, and show encouraging anti-tumor outcomes.

Cetuximab and PD-1 inhibitors are believed to have a synergistic mechanism of action in SCCHN treatment. Preliminary data of early-phase studies have shown promising results from combining immune checkpoint inhibitors with cetuximab.

“Junshi Biosciences has always been concerned with the unmet treatment needs of patients, and has highly prioritized tumors that have a high prevalence and require urgent treatment,” said Dr. Ning Li, CEO of Junshi Biosciences. “Research has shown that anti-PD-1 combination therapy could enhance clinical efficacy of anti-PD-1 mAb, and that the future direction of tumor treatment will increasingly focus on combination therapy, using multiple mechanisms of action to fight tumors. Merck’s Cetuximab, which has been approved for treatment of head and neck squamous cell carcinoma, is one of the ideal drug candidates for combined use with anti-PD-1 drugs. We look forward to benefiting more patients with the combination of targeted therapy and immunotherapy in the treatment of SCCHN.”

“The partnership combines the strengths of both Merck and Junshi Biosciences to explore the effects of targeted and immune combination therapy, with the purpose of providing better and more effective cancer treatment for patients with head and neck cancers in China,” said Rogier Janssens, Managing Director and General Manager of Merck’s Biopharma business in China. “This collaboration demonstrates our company’s strong commitment to advancing cancer care and easing the burden the disease poses on patients with R/M SCCHN and other cancer types.”

About TUOYI® (toripalimab)

Toripalimab is an anti-PD-1 monoclonal antibody developed by Junshi Biosciences. Toripalimab received its first approval for 2nd line treatment of metastatic melanoma on December 17, 2018 in China and was commercially launched in February 2019.

About Erbitux® (Cetuximab)

ERBITUX® is an IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of ERBITUX® is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth. Based on in vitro evidence, ERBITUX® also targets cytotoxic immune effector cells towards EGFR-expressing tumor cells (antibody-dependent cell-mediated cytotoxicity [ADCC]).

ERBITUX® has already obtained market authorization in over 100 countries worldwide for the treatment of RAS wild-type metastatic colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck. Merck licensed the right to market ERBITUX®, a registered trademark of ImClone LLC, outside the U.S. and Canada from ImClone LLC, a wholly owned subsidiary of Eli Lilly and Company, in 1998.

About Junshi Biosciences

Established in 2012, Junshi Biosciences is committed to developing first-in-class and best-in-class drugs through original innovation and becoming a pioneer in the area of translational medicine to provide patients with effective and affordable treatment options. On December 24, 2018, Junshi Biosciences was listed on the Main Board of the Stock Exchange of Hong Kong with the stock code: 1877.HK. The Company has established a diversified R&D pipeline comprising 21 drug candidates with therapeutic areas covering cancer, metabolic diseases, autoimmune diseases, neurologic diseases, and infectious disease. Product types include monoclonal antibodies, fusion proteins, antibody-drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP-facilities at Shanghai and Suzhou, Junshi Biosciences has established the manufacturing infrastructure to support commercialization and provide our partners and patients with high-quality products through a global supply chain network.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of 16.2 billion Euros in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

Contact Information

IR Team:

Junshi Biosciences
[email protected]  
+ 86 021-2250 0300

Solebury Trout
Michael Levitan
[email protected]
+ 1 646.378.2920

PR Team:

Junshi Biosciences
Zhi Li
[email protected]
+ 86 021-6105 8800

Solebury Trout
Zara Lockshin
[email protected]
+ 1 646.378.2960

_________________
1 Chen W, et al. CA Cancer J Clin 2016; 66:115-32
2 Guo Y, Bai CM, Li ZM. Update in immunotherapy for recurrent and metastatic squamous cell carcinoma of head and neck [J]. J Cancer Control Treat, 2019, 32(7):562-579.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.